INmune Bio Inc. short interest in 2021
In 2021, INmune Bio Inc.'s disclosed short interest ran from 4.04% of shares outstanding on 15 Jan 2021 to 5.83% on 31 Dec 2021, a change of +1.79 percentage points. The year's high was 7.83% on 30 Jul 2021 and its low 2.71% on 26 Feb 2021, averaging 5.33% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.51 days on 30 Jun 2021. Full history: INmune Bio Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 4.04% (15 Jan 2021)
- End of year
- 5.83% (31 Dec 2021)
- Change
- +1.79 pp
- High
- 7.83% (30 Jul 2021)
- Low
- 2.71% (26 Feb 2021)
- Average
- 5.33%
- Highest days to cover
- 6.51 (30 Jun 2021)
- SEC filings marked
- 8
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 4.04% | 2.14 | |
| 29 Jan 2021 | 3.58% | 1.00 | |
| 12 Feb 2021 | 3.33% | 1.22 | |
| 26 Feb 2021 | 2.71% | 1.72 | |
| 15 Mar 2021 | 3.30% | 1.99 | 10-K filed, results (8-K) |
| 31 Mar 2021 | 3.64% | 5.56 | |
| 15 Apr 2021 | 3.84% | 6.11 | |
| 30 Apr 2021 | 5.32% | 3.96 | |
| 14 May 2021 | 5.29% | 6.21 | 10-Q filed, results (8-K) |
| 28 May 2021 | 6.44% | 5.94 | |
| 15 Jun 2021 | 6.42% | 3.79 | |
| 30 Jun 2021 | 6.33% | 6.51 | |
| 15 Jul 2021 | 6.84% | 1.08 | |
| 30 Jul 2021 | 7.83% | 1.71 | |
| 13 Aug 2021 | 6.55% | 3.10 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 5.87% | 2.94 | |
| 15 Sep 2021 | 5.60% | 1.12 | |
| 30 Sep 2021 | 6.38% | 2.69 | |
| 15 Oct 2021 | 5.76% | 5.24 | |
| 29 Oct 2021 | 6.27% | 6.32 | |
| 15 Nov 2021 | 5.76% | 2.92 | 10-Q filed, results (8-K) |
| 30 Nov 2021 | 5.59% | 3.94 | |
| 15 Dec 2021 | 5.37% | 4.08 | |
| 31 Dec 2021 | 5.83% | 5.24 |
See also: INmune Bio Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.